Insider Selling: Celldex Therapeutics (NASDAQ:CLDX) Insider Sells 49,298 Shares of Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) insider Richard Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the sale, the insider owned 20,833 shares in the company, valued at $499,992. The trade was a 70.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Celldex Therapeutics Trading Up 1.8%

Shares of Celldex Therapeutics stock traded up $0.45 during trading hours on Monday, reaching $26.00. 1,183,718 shares of the company’s stock were exchanged, compared to its average volume of 1,018,647. The stock has a market cap of $1.73 billion, a P/E ratio of -8.64 and a beta of 1.36. The company has a 50 day moving average of $25.56 and a two-hundred day moving average of $22.88. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $29.05.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. As a group, analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CLDX. Handelsbanken Fonder AB grew its stake in Celldex Therapeutics by 2.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock valued at $440,000 after buying an additional 500 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Celldex Therapeutics by 7.0% in the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 844 shares during the period. Finally, Nisa Investment Advisors LLC grew its stake in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 881 shares in the last quarter.

Wall Street Analyst Weigh In

CLDX has been the subject of several recent analyst reports. Citigroup cut their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday, August 20th. Wells Fargo & Company cut their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, August 20th. Barclays decreased their price objective on shares of Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $62.00 price target on shares of Celldex Therapeutics in a report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.80.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.